NIH 赞助了一项临床试验，旨在研究一种治疗肠道病毒 D68 的单克隆抗体，该病毒会导致严重的呼吸道和神经系统疾病，如 AFM，目前尚无 FDA 批准的治疗方法。 NIH sponsors a clinical trial for an investigational monoclonal antibody to treat enterovirus D68, causing severe respiratory and neurological diseases like AFM, with no FDA-approved treatments.
美国国立卫生研究院 (NIH) 赞助了一项临床试验，以检验一种研究性单克隆抗体治疗肠道病毒 D68 (EV-D68) 的安全性，该病毒会引发严重的呼吸道和神经系统疾病，如急性弛缓性脊髓炎 (AFM)，类似于脊髓灰质炎。 The NIH sponsors a clinical trial to examine the safety of an investigational monoclonal antibody for treating enterovirus D68 (EV-D68), which triggers severe respiratory and neurological diseases like acute flaccid myelitis (AFM), resembling polio. 科学家们旨在了解 AFM，自 2014 年以来，AFM 在美国每隔一年就会激增，但目前尚无 FDA 批准的针对严重 EV-D68 感染或 AFM 的治疗方法。 Scientists aim to understand AFM, which surges every other year in the US since 2014, and there are no FDA-approved treatments for severe EV-D68 infection or AFM.